News stories about Athersys (NASDAQ:ATHX) have been trending somewhat positive this week, Accern Sentiment reports. Accern ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Athersys earned a coverage optimism score of 0.21 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 45.9713941491008 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the media headlines that may have impacted Accern Sentiment Analysis’s analysis:
- Athersys, Inc. (NASDAQ:ATHX) – Early Moves to Watch – The Investor Guide (wallstreetnews24.com)
- Athersys Inc (ATHX) Sees The Tape Move Mid-Market – MTNV (mtnvnews.com)
- Athersys Multistem Partner Healios KK Delays Implementation Of Critical Phase III TREASURE Trial – Seeking Alpha (seekingalpha.com)
- Athersys, Inc. (ATHX) Downgraded by Zacks Investment Research (americanbankingnews.com)
Several equities research analysts recently commented on the company. ValuEngine upgraded Athersys from a “sell” rating to a “hold” rating in a report on Friday. Zacks Investment Research cut Athersys from a “buy” rating to a “hold” rating in a research report on Thursday. Finally, Maxim Group reaffirmed a “buy” rating and set a $12.00 price objective on shares of Athersys in a research report on Friday, September 1st. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Athersys currently has an average rating of “Buy” and a consensus price target of $7.08.
Athersys (ATHX) traded up 3.26% on Friday, reaching $2.22. The company had a trading volume of 1,731,320 shares. The stock’s 50 day moving average is $1.72 and its 200-day moving average is $1.52. Athersys has a 1-year low of $1.02 and a 1-year high of $2.30. The stock’s market capitalization is $252.88 million.
Athersys (NASDAQ:ATHX) last issued its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.06). The firm had revenue of $0.67 million for the quarter, compared to analysts’ expectations of $0.96 million. Athersys had a negative return on equity of 91.02% and a negative net margin of 936.77%. The firm’s revenue for the quarter was up 12.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.08) EPS. On average, equities analysts predict that Athersys will post ($0.24) EPS for the current fiscal year.
Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.
Receive News & Ratings for Athersys Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys Inc. and related companies with our FREE daily email newsletter.